127 related articles for article (PubMed ID: 25536616)
1. Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines.
Dirican A; Erten C; Atmaca H; Bozkurt E; Kucukzeybek Y; Varol U; Oktay Tarhan M; Karaca B; Uslu R
J BUON; 2014; 19(4):1055-61. PubMed ID: 25536616
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Varol U; Degirmenci M; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Sanli UA; Uslu R
Tumour Biol; 2015 Feb; 36(2):779-86. PubMed ID: 25293519
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines.
Asbagh LA; Uzunoglu S; Cal C
Int Braz J Urol; 2008; 34(3):355-63; discussion 364. PubMed ID: 18601766
[TBL] [Abstract][Full Text] [Related]
5. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Dirican A; Atmaca H; Bozkurt E; Erten C; Karaca B; Uslu R
Clin Transl Oncol; 2015 Feb; 17(2):145-51. PubMed ID: 25060568
[TBL] [Abstract][Full Text] [Related]
6. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines.
Karabulut B; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Uslu R
Mol Biol Rep; 2011 Jan; 38(1):249-59. PubMed ID: 20349282
[TBL] [Abstract][Full Text] [Related]
7. Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination.
Sanli UA; Gorumlu G; Erten C; Gul MK; Cengiz E; Kucukzeybek Y; Karaca B; Atmaca H; Uzunoglu S; Karabulut B; Uslu R
Cell Biol Int; 2009 Nov; 33(11):1165-72. PubMed ID: 19716895
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
[TBL] [Abstract][Full Text] [Related]
9. Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species.
Koka PS; Mondal D; Schultz M; Abdel-Mageed AB; Agrawal KC
Exp Biol Med (Maywood); 2010 Jun; 235(6):751-60. PubMed ID: 20511679
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro.
Mani J; Vallo S; Barth K; Makarević J; Juengel E; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):250-5. PubMed ID: 22450844
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines.
Gokalp C
Mol Biol Rep; 2020 Oct; 47(10):7675-7683. PubMed ID: 32989500
[TBL] [Abstract][Full Text] [Related]
12. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic activities of thymoquinone, an active ingredient of black seed (Nigella sativa), in cervical cancer cell lines.
Ichwan SJ; Al-Ani IM; Bilal HG; Suriyah WH; Taher M; Ikeda MA
Chin J Physiol; 2014 Oct; 57(5):249-55. PubMed ID: 25241984
[TBL] [Abstract][Full Text] [Related]
14. Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Surmeli Z; Gursoy P; Erdogan AP; Bozkurt E; Atmaca H; Uzunoglu S; Sezgin C; Şanlı UA; Uslu R; Karaca B
Tumour Biol; 2016 Mar; 37(3):3665-73. PubMed ID: 26462835
[TBL] [Abstract][Full Text] [Related]
15. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa.
Majdalawieh AF; Fayyad MW; Nasrallah GK
Crit Rev Food Sci Nutr; 2017 Dec; 57(18):3911-3928. PubMed ID: 28140613
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone from Nigella sativa was more potent than cisplatin in eliminating of SiHa cells via apoptosis with down-regulation of Bcl-2 protein.
Ng WK; Yazan LS; Ismail M
Toxicol In Vitro; 2011 Oct; 25(7):1392-8. PubMed ID: 21609759
[TBL] [Abstract][Full Text] [Related]
19. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis.
Rouhrazi H; Turgan N; Oktem G
Biotech Histochem; 2018; 93(2):77-88. PubMed ID: 29300112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
